InnoPharmax
因華生技製藥股份有限公司
InnoPharmax is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is D07001 (Phase 3; recruiting, Biliary Tract Cancer (BTC)), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| D07001 | — | Phase 3; recruiting | Biliary Tract Cancer (BTC) | Taiwan, United States | 2026-07-30 | Trial registry |
| D07001-F4 | — | Phase 1; completed | Advanced Solid Malignancies; Malignant Lymphomas | Taiwan | 2019-07-08 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.